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a b s t r a c t
The biological basis for the poor immunogenicity of unadjuvanted avian inﬂuenza A virus vaccines in
mammals is not well understood. Here, we mutated the hemagglutinin (HA) of two H1N1 virus vaccines
to determine whether virus receptor binding speciﬁcity contributes to the low immunogenicity of avian
inﬂuenza virus vaccines. Mutations were introduced into the HA of an avian inﬂuenza virus, A/Duck/New
York/15024–21/96 (Dk/96) which switched the binding preference from α2,3- to α2,6-linked sialic acid
(SA). A switch in receptor speciﬁcity of the human A/South Carolina/1/18 (SC/18) virus generated a
mutant virus with α2,3 SA (avian) binding preference. Inactivated vaccines were generated and
administered to mice and ferrets intramuscularly. We found that the vaccines with human receptor
binding preference induced slightly higher antibody titers and cell-mediated immune responses
compared to their isogenic viruses with avian receptor binding speciﬁcity. Upon challenge with DK/96
or SC18 virus, differences in lung virus titers between the vaccine groups with different receptor-binding
speciﬁcities were minimal. Overall, our data suggest that receptor binding speciﬁcity contributes only
marginally to the immunogenicity of avian inﬂuenza vaccines and that other factors may also be
involved.
Published by Elsevier Inc.
Introduction
Avian inﬂuenza A subtype viruses continue to pose a signiﬁcant
threat to human health. Multiple subtypes of avian inﬂuenza
viruses including H5, H6, H7, H9 and H10 have caused infection
in humans primarily through direct transmission from infected
poultry (Butt et al., 2005; Koopmans et al., 2004; Subbarao and
Joseph, 2007; Yuan et al., 2013). Human infection with avian
inﬂuenza viruses can be severe, causing high mortality (up to
58%) as reported for H5N1 virus infection (Beigel et al., 2005). In
the spring of 2013, a new subtype of avian inﬂuenza A(H7N9) virus
emerged in China (Gao et al., 2013), and as of February 28, 2014,
the World Health Organization (WHO) had reported over 375
conﬁrmed cases of human infection, with a case fatality rate of
approximately 30% (http://www.who.int/en/). The increasing
numbers of human avian inﬂuenza cases highlight the need to
strengthen prevention and treatment efforts.
Vaccination has been the principal public health method for
preventing and controlling seasonal inﬂuenza in humans and the
design of more effective vaccines against avian inﬂuenza A viruses
is an important part of pandemic preparedness. A variety of avian
inﬂuenza virus vaccines, including inactivated (whole, split or
subunit), live attenuated vaccines or recombinant protein vaccines
have been developed, some of which have been tested in humans
(Atmar et al., 2006; Bresson et al., 2006; Couch et al., 2012; Keitel
et al., 2008; Patel et al., 2012; Tretyakova et al., 2013). Although
the efﬁcacy of avian inﬂuenza vaccines varies depending on the
vaccine formulations and routes of administration, most of the
studies agree that unadjuvanted avian inﬂuenza vaccines are
poorly immunogenic compared to seasonal H1N1 and H3N2
inﬂuenza virus vaccines (Atmar et al., 2006; Bresson et al., 2006;
Couch et al., 2012; Keitel et al., 2008; Patel et al., 2012). In one
study, a two-dose regimen of 90 mg of H5 hemagglutinin (HA)
subvirion vaccine resulted in only 58% of recipients showing a
neutralizating antibody titer of 1:40 or greater (Treanor et al.,
2006). In contrast, approximately 90% of adults demonstrated
similar antibody titers when a single-dose of 15 mg of 2009 H1
HA vaccine was administered (Zhu et al., 2009). While these
differences may, in part, be due to differences in priming, there
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remains a need for further research into improving the immuno-
genicity of vaccines that use avian inﬂuenza virus seed strains.
The HA is the major target of host immune recognition and an
anti-HA antibody can provide protection against inﬂuenza virus
infection by blocking viral attachment to the host cell (Han and
Marasco, 2011). The HA glycoprotein is also responsible for both
receptor binding and the subsequent fusion of viral and host
endosomal membranes (Skehel and Wiley, 2000). HA recognizes a
common ligand, the terminal sialic acid (SA) presented on either
glycoproteins or glycolipids (Skehel and Wiley, 2000). Structurally,
the HA receptor binding site is located in a shallow depression in
the globular head region of the HA trimer protein and is composed
of well-known structural elements such as the 220 loop, 130 loop,
150 loop and 190 helix (H3 numbering) (Skehel and Wiley, 2000).
Although the overall structure of HA is conserved across all
inﬂuenza A subtype viruses, the ﬁne variations in the HA receptor
binding pocket confer recognition speciﬁcity for the speciﬁc
linkage between terminal SA and the penultimate galactose
residue (Xu et al., 2013). In general, avian inﬂuenza viruses
preferentially bind to α2,3-linked SA whereas human inﬂuenza
viruses preferentially attach to host airway cells expressing α2,6-
linked SA (Connor et al., 1994; Rogers and Paulson, 1983).
Sequence alignments of inﬂuenza A HA genes have identiﬁed
key receptor speciﬁcity determining residues and as few as one or
two amino acid mutations are sufﬁcient to alter the receptor-
binding speciﬁcity of some inﬂuenza A viruses. For example, two
residues at positions 226 and 228 in the HA of H2, H3 and H6
subtypes directly contribute to viral receptor speciﬁcity; L226/
G228 for α2,6 SA binding, Q226/G228 for α2,3 SA binding and
L226/S228 showing dual receptor binding (Chen et al., 2012;
Connor et al., 1994; Rogers and Paulson, 1983). For inﬂuenza H1
subtype, the HA receptor speciﬁcity-determining residues are
located at positions 190 and 225 (H3 numbering); human inﬂu-
enza viruses generally have an Asp amino acid residue at positions
190 and 225, whereas inﬂuenza viruses with Glu-190/Gly-225
confer binding speciﬁcity to an avian-type receptor (Glaser et al.,
2005; Zhang et al., 2013). However, for other subtypes of inﬂuenza
the key residues governing receptor binding speciﬁcity are less
deﬁned and it appears that the amino acids outside of the receptor
binding pocket also affect receptor binding speciﬁcity as recently
shown among avian H5N1 viruses (Herfst et al., 2012; Imai et al.,
2012). Moreover, viral receptor binding speciﬁcity affects viral
pathogenesis and transmissibility (Qi et al., 2009; Tumpey et al.,
2007).
Recently, it was demonstrated that live attenuated inﬂuenza H2
and H6 vaccine viruses with dual receptor binding are able to elicit
better immune responses in ferrets compared to viruses with α2,
3-SA binding speciﬁcity (Chen et al., 2012; Connor et al., 1994;
Rogers and Paulson, 1983). In the current study, we evaluated the
contribution of receptor binding speciﬁcity to the immunogenicity
and effectiveness of inactivated inﬂuenza vaccines. We altered the
receptor binding preference of two H1N1 viruses and compared
both humoral and cell-mediated immune responses in mice and
ferrets following vaccination and found that viruses with prefer-
ential afﬁnity for α2,6-linked SA only moderately improved the
immunogenicity of inactivated vaccines.
Results
Altering receptor binding speciﬁcity has no signiﬁcant effect on viral
ﬁtness and antigenicity
It has been shown previously that the receptor binding pre-
ference of an avian inﬂuenza H1N1 (DK/96) virus can be altered by
only two mutations at residues E190D and G225D of the HA gene
(Van Hoeven et al., 2009). Before we generated inactivated DK/96-
wt and DK/96 HA mutant (DK/96-Hu) virus vaccines, we char-
acterized the binding properties of the rescued viruses and
determined whether altering receptor binding speciﬁcity affects
viral ﬁtness. Both parental and mutant viruses were assessed for
their ability to agglutinate turkey RBCs resialylated with either
α2-3- or α2-6-linked sialosides. As expected, DK/96-wt virus was
found to agglutinate α2,3 sialylated RBCs only, whereas DK/96-Hu
virus showed preferential agglutination of α2,6 sialylated RBCs
(not shown). Mice were infected with 106 or 103 EID50 of DK/96-wt
or DK/96-Hu virus and viral titers in lung tissues at the peak of
virus infection (day 4 post-inoculation) were compared. As shown
in Fig. 1A, both viruses replicate efﬁciently in mouse lung tissues
with the DK/96-wt virus showing slightly higher titers; however
the differences are not signiﬁcant at either inoculation dose.
In a reciprocal experimental approach, the receptor binding
preference of the human inﬂuenza H1N1 1918 (SC/18) virus was
altered from human- to avian-like by two HA mutations at
residues 190 and 225. It has been documented that these two
point mutations in the HA gene are sufﬁcient to change the
receptor binding preference from α2,6- to α2,3-SA (Glaser et al.,
2005). The HA and NA genes from SC/18-wt and α2,3 SA receptor
binding mutant (SC/18-Av) virus, respectively, were rescued on the
PR8 virus backbone. As expected, SC/18-wt was found to aggluti-
nate α2,6 sialylated RBCs whereas SC/18-Av recombinant virus
showed preferential agglutination of α2,3 sialylated RBCs (not
shown). We found that altering receptor binding speciﬁcity for
SC/18/PR8 virus did not signiﬁcantly change the ability of the virus
Fig. 1. DK/96 and SC/18 virus replication in mouse lung tissues. Groups of 5 mice are intranasally (i.n.) inoculated with 106 EID50 or 103 EID50 of DK/96-wt or DK/96-Hu (HA-
190D_225D) viruses (A) or with 106 PFU or 103 PFU of SC/18-wt or SC/18-Av (HA-190E-225G) viruses (B), and the viral titers in lung tissues at day 4 post-infection are titrated
in eggs or MDCK cells and expressed as mean log10 EID50 or log10 PFU per mlþstandard deviation (SD). There is no signiﬁcance in viral titers between the wt groups and their
respective isogenic control virus groups based on two-way analysis of variance (ANOVA, p40.05).
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to replicate in mouse lungs; mice showed comparable virus titers
on day 4 post-inoculation following either 106 or 103 PFU of SC/18-
wt or SC/18-Av virus inoculation (Fig. 1B).
Next, we evaluated whether changing the receptor binding
speciﬁcity had any effect on viral antigenicity following virus
infection. The convalescent sera from mice inoculated with 106
EID50 of DK/96-wt or DK/96-Hu virus were collected at 21 days
post-inoculation. No convalescent SC/18 sera were available for
follow-up serology due to the high virulence of the virus in mice.
The HI assays were initially conducted with both turkey and horse
erythrocytes. Turkey red blood cells (TRBCs) were used to detect
the serum HI titers against DK/96-Hu because the mutant virus
failed to agglutinate horse red blood cells (HRBCs). Conversely, we
found that using HRBCs to detect serum HI titer against DK/96-wt
virus (expressing α2,3 SA) gave approximately 2-fold higher titers
than that using TRBCs (data not shown), and therefore, the HI
titers against DK/96-wt virus using HRBCs are shown (Table 1).
Both DK/96-wt and DK/96-Hu virus inoculations induced robust
serum antibody responses in mice. In general, the HI titers in
response to infection correlated well with neutralizing antibody
levels, although neutralizing antibody responses were consistently
higher. The HI titers against DK-96-Hu virus antigen were con-
sistently 2-fold lower than the titers against DK/96-wt virus
regardless of the viruses used for infection (geometric mean titer
[GMT] of 52 versus 121, 67 versus 134). In the neutralization assay,
antibody titers against mutant DK/96-Hu and DK/96-wt were
within 2-fold of each other (Table 1). Overall, our results demon-
strated that changing receptor binding speciﬁcity for the H1N1
viruses had no signiﬁcant effect on viral antigenicity or viral
replication in mice.
Immunogenicity and protective efﬁcacy of an inactivated avian
inﬂuenza vaccine with α2,6 SA (human-like) binding preference
We next evaluated the contribution of receptor binding speci-
ﬁcity to the immunogenicity and effectiveness of an inactivated
avian inﬂuenza H1N1 virus vaccine. Formaldehyde-inactivated
whole-virus vaccines derived from Dk/96-wt and DK/96-Hu
viruses were used to vaccinate groups of mice in one or two dose
vaccination regimen. In the single dose study, ten mice per group
were inoculated with vaccine doses ranging from 0.25 to 10 mg. We
found that at higher vaccine doses (10, 5, and 2.5 mg), DK/96-Hu
vaccinated groups showed approximately 2–4 fold higher HI titers
(Fig. 2A) and about 4-fold higher neutralization titers (Fig. 2B)
against both homologous and Dk/96-wt viruses compared to
antibody responses induced by DK/96-wt vaccine. At lower doses
(0.5 and 0.25 mg), both Dk/96-wt and DK/96-Hu vaccines elicited
weaker antibody responses and the difference in titers between
the two vaccine groups was less evident compared to higher
vaccine doses (Fig. 2A and B). The vaccine experiment was
repeated once with a set of independently prepared DK/96 virus
vaccines. At the same vaccine doses, we were able to conﬁrm that
the HI and neutralization titers were approximately 2–4 fold
higher among those mice that received the DK/96-Hu vaccine
(α2,6 SA binding preference) compared to Dk/96-wt (2,3 SA
binding preference) vaccinated mice (data not shown).
Table 1
Geometric mean of HI and neutralizing (neut) antibody titers from mouse seraa
Virus antigen HI titerb Neut. titerb
Sera raised against Sera raised against
DK/96-WT DK/96-Hu DK/96-WT DK/96-Hu
DK/96-wt 121 (80–160) 134 (80–160) 320 (160–640) 452 (320–640)
DK/96-Hu 52 (20–80) 67 (40–80) 425 (160–640) 761 (640–1280)
a Convalescent serum samples from individual mice (5 per group) are collected
21 days post-inoculation with 106 EID50 of the virus indicated.
b Samples are tested for HI and neutralization antibody activity against either
DK/96-wt or mutant DK/96-Hu virus. Geometric mean titers (with range in
parentheses) are shown as the reciprocal of the highest dilution of serum that
completely inhibits haemagglutination (HI) or that neutralizes 100 PFU of infec-
tious virus (neut).
Fig. 2. Cross-reactive antibody titers upon primary vaccination with DK/96 vaccine.
Groups of 10 mice are vaccinated intramuscularly (i.m.) with 100 ml of PBS-diluted
inactivated whole virus ranging from 0.25 mg to 10 mg (total protein) per mouse.
The cross-reactive HI (A) and neutralizing antibody (B) titers of the vaccinated
mouse sera at 28 days post-primary vaccination are tested against DK/96-wt and
DK/96-Hu viruses. The graph represents the geometric mean value of the HI titers
shown as log2 scaleþSD. Statistical signiﬁcance was determined by two-way
ANOVA and Bonferroni post-test. An asterisk indicates that the antibody titers
between DK/96-wt and DK/96-Hu vaccine groups at indicated dosage are sig-
niﬁcantly different with po0.05.
Table 2
Geometric mean of hemagglutination-inhibition (HI) and neutralizing (neut)
antibody titers of mice vaccinated with two-doses of DK/96-wt or DK/96-Hu
inactivated virus vaccine.
Virus antigen Vaccine dose (mg) HI titers of mouse sera againsta
DK/96-wt DK/96-wtb DK/96-Hub
HI titer Neut. titer HI titer Neut. titer
10 320 253 289 296
5 293 172 320 242
2.5 274 nd 320 nd
a Mice receive a two-dose regimen of the indicated vaccine 4 weeks apart.
Serum samples from individual mice (10 per group) are collected 30 days post-
boost. nd¼not done.
b Samples are tested for HI and neutralization antibody activity against DK/96-
wt virus. Geometric mean titers are shown as the reciprocal of the highest dilution
of serum that completely inhibits hemagglutination (HI) or that neutralizes
100 PFU of infectious virus (neut). There is no signiﬁcance in titers between
DK/96-wt and DK/96-Hu groups by two-way ANOVA and Bonferroni post-test.
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We next compared the antibody titers after boost for the
groups vaccinated with high doses of inactivated viruses. As
shown in Table 2, both vaccine groups exhibited a signiﬁcant
increase in the HI titers following boost compared with primary
vaccination, but the difference in antibody titers previously
observed between two groups after single dose vaccination
was diminished. Mouse sera obtained 30 days after vaccine
boost, showed HI titers that ranged from 256 to 512 (GMT 274 to
320) for vaccine groups inoculated with doses of 10, 5, and
2.5 mg (Table 2). However, the differences in the HI and neu-
tralization titers between the two vaccine groups were less
evident compared to that observed in single-dose vaccine
studies (Table 2 versus Fig. 2). One additional time-point of
serum collection was taken at 200 days post-boost in attempt to
show differences in antibody responses between DK/96-wt and
DK/96-Hu vaccine groups. The antibody responses from the two
virus groups dropped to similar levels over the extended period
and there were no signiﬁcant difference in HI titers (not shown).
Our results suggest that the avian H1N1 virus vaccine
with human receptor (α2,6 SA) binding preference had a
modest advantage compared to the DK/96-wt vaccine in indu-
cing antibody titers following primary vaccination; however,
the response was less pronounced following prime-boost
vaccination.
Since the differences in antibody responses between DK/96-wt
and DK/96-Hu vaccine groups were greatest after a single vaccina-
tion, the mice that received 5.0, 0.5 or 0.25 mg of vaccine were
challenged with 106 EID50 of DK/96-wt virus at 32 days post-
primary vaccination and lung titers were determined at day 4 p.c.
As shown in Fig. 3, DK/96-wt virus replicates to approximately 107
EID50 in the lungs of control (PBS) mice. In general, vaccination
with either DK/96-wt or DK/96-Hu virus provided some level of
protection against viral replication in the lung at all vaccine doses
tested. At vaccine doses of 5.0 and 0.5 mg, titers of infectious virus
among DK/96-Hu immunized mice were reduced approximately
10-fold compared to DK/96-wt vaccine group; however, this did
not reach statistical signiﬁcance (p¼0.08–0.1). At the lower
vaccine dose (0.25 mg) the viral lung titers between vaccine groups
were comparable, which was consistent with the negligible
difference in antibody titers between DK/96-wt and DK/96-Hu
vaccine groups at the same vaccine dose. Taken together, these
results demonstrated that the inactivated avian H1 vaccine show-
ing speciﬁc binding for α2,6 SA induced approximately 2–4 fold
higher antibody response, which correlated with modestly
improved protection against viral challenge.
Immunogenicity and protective efﬁcacy of SC/18 virus with α2,3 SA
(avian) binding preference
In a reciprocal experimental approach, inactivated virus vac-
cines were made from a recombinant virus containing the wt HA
and NA genes from SC/18 virus (SC/18-wt) or its avian receptor
mutant (SC/18-Av) virus. Mice (10 per group) were immunized
once with 10, 2.5 or 0.25 mg of vaccine. The antibody responses
were detected at 28 days post-vaccination by the HI assay. As
shown in Fig. 4A, antibody titers induced by SC/18-wt are slightly
higher than those induced by the SC/18 avian receptor mutant
virus at dose levels of 10 and 2.5 mg, but the differences are
generally less than two-fold and not statistically signiﬁcant. At
the low (0.25 mg) dose, both vaccines induced poor antibody
responses and there were no differences in HI antibody titers.
In both vaccine groups, antibody titers were boosted after a second
immunization, however the titer differences between the two
vaccines were negligible (data not shown).
To compare the protective efﬁcacy following SC/18-wt or avian
receptor mutant (SC/18-Av) virus vaccination, immune and PBS-
control mice were challenged with 106 PFU of SC/18-wt virus after
primary vaccination. The mice from the PBS control group showed
rufﬂed fur and weight loss by day 4 p.c. and virus in lung tissues
Fig. 3. The protective efﬁcacy of the vaccination with DK/96 virus upon challenge.
Groups of 5 mice vaccinated with 5, 0.5 or 0.25 mg of DK/96-wt or DK/96-Hu virus
vaccines are challenged with 106 EID50 of DK/96-wt virus at 30 days post-primary
vaccination. Lungs were collected at day 4 post-challenge and titrated in eggs,
expressed as mean log10 EID50 per mlþSD. There is no signiﬁcance in viral titers
between DK/96-wt and DK/96-Hu vaccine groups based on two-way ANOVA
(p40.05).
Fig. 4. Cross-reactive antibody titers and the protective efﬁcacy upon primary
vaccination with SC/18 vaccine. (A) Groups of 10 mice are vaccinated with 100 ml of
PBS-diluted inactivated whole virus vaccines at doses of 10 mg, 2.5 mg or 0.25 mg per
mouse. The cross-reactive HI titers of the vaccinated mouse sera at 28 days post-
primary vaccination are tested against SC/18-wt and SC/18-Av viruses. The graph
represents the geometric mean value of HI antibody titers shown as log2
scaleþstandard deviation (SD). The HI titers between SC/18-wt and SC/18-Av at
any vaccination dose are not statistically different as analyzed by two-way ANOVA
and Bonferroni post-test (B). At 30 days post-primary vaccination, groups of 5 mice
are challenged with 106 PFU of SC/18-wt virus and the lung titers at day 4 post-
challenge are shown as the mean log10 PFU per mlþSD. There is no signiﬁcance in
lung titers between SC/18-wt and SC/18-Av vaccinated groups based on two-way
ANOVA (p40.05).
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reached mean peak titers of 105.8 PFU/ml (Fig. 4B). Vaccination
with doses of 10 mg and 2.5 mg resulted in reduced viral titers
compared to those of the PBS group; however, the difference in
viral lung titers between SC/18-wt and SC/18-Av vaccine groups
was not statistically signiﬁcant. At vaccine dose of 0.25 mg, both
vaccines failed to signiﬁcantly reduce viral replication compared to
that of the PBS control group. Overall, our results suggest that
changing receptor binding speciﬁcity of SC/18 virus from human-
to avian-like has minimal effect on viral immunogenicity of
inactivated vaccines in mice.
The cellular immune responses of wild-type and mutant virus
vaccinated mice
Next we compared the frequency of vaccine-induced antibody-
secreting (ASC) B cells and cytokine secreting T cell responses
among mice administered with one dose of 10 or 2.5 μg of Dk/96-
wt and Dk/96-Hu vaccines. We used the ELISPOT assay, which has
proven to be a sensitive tool for detecting cellular immunity
following inﬂuenza vaccination (Lindemann et al., 2006) to mea-
sure the frequency of antigen-speciﬁc IgG secreting B cells from
spleen tissues. As shown in Fig. 5A, the frequency of virus-speciﬁc
IgG ASCs in spleen tissues signiﬁcantly increases in mice immu-
nized with 10 mg DK/96-Hu vaccine as compared to that of DK/96-
wt vaccine. DK/96-Hu vaccination also increased the frequency of
ASCs even at the lower vaccine dose of 2.5 mg. For the 1918/PR8
virus vaccine, 2.5 mg of SC/18-wt virus vaccine induced approxi-
mately 4-fold higher frequency of ASCs in comparison to the same
dose of SC/18-Av vaccine (Fig. 5A; right panel). At the lower
vaccine dose of 0.25 mg, both vaccines induced a relatively low
frequency of ASCs and there was no difference between the two
vaccine groups.
We next compared the frequency of virus-speciﬁc cytokine
secreting CD4þ or CD8þ T cells upon antigen re-stimulation
in vitro. As shown in Fig. 5B (left panel), mice immunized with
2.5 mg of DK/96-Hu vaccine show a higher frequency of IFN-γ
secreting CD4 as compared to that of the DK/96-wt vaccine group.
Similarly, the SC/18-wt vaccine (with human-like α2,6 SA) induced
a higher frequency of IFN-γ secreting CD4þ cells, but not CD8þ
cells, as compared to that of SC/18-Av mutant vaccine (Fig. 5B;
right panel). However this difference was not observed at the
other two vaccine doses. In addition, both vaccines induced a very
low level of IFN-γ production by CD8þ T cells and no signiﬁcant
increased frequency of CD8þ IFN-γþ cells was observed among the
groups (Fig. 5A and B). In summary, our data demonstrated that
H1N1 inﬂuenza vaccines with human receptor binding preference
(α2,6 receptor binding afﬁnity) induced a somewhat higher
frequency of ASC B cells and IFN-γ cytokine secreting CD4þ , but
not CD8þ T cells, as compared to their counterpart vaccines with
avian receptor binding preference.
Immunogenicity and protective efﬁcacy of DK/96-wt and DK/96-Hu
virus vaccines in ferrets
Ferrets are considered to be the most suitable animal model for
inﬂuenza vaccine efﬁcacy studies (Belser et al., 2011). To further
explore whether the viral receptor binding preference for α2,3 SA
contributes to the relatively poor immunogenicity of avian inﬂu-
enza virus vaccines in humans, we compared the antibody
responses of DK/96-wt and DK/96-Hu in ferrets. Groups of 4–6
Fig. 5. The cell-mediated immune response upon vaccination with 1918 virus. (A) Groups of 3–5 mice are vaccinated i.m. with DK/96-wt and DK/96-Hu (10 or 2.5 mg) or SC/
18-wt and SC/18-Av (2.5 or 0.25 mg) vaccines. Fourteen days later, spleen tissues are harvested and the frequency of virus-speciﬁc IgGþASCs are measured by ELISPOT assay.
The number of virus-speciﬁc IgGþASCs is normalized against the number of total IgGþsecreting ASCs and presented as % Ag-speciﬁc IgGþB cells. (B) Mice are vaccinated
with DK/96-wt and DK/96-Hu (10 or 2.5 mg) or SC/18-wt and SC/18-Av (2.5 or 0.25 mg). Fourteen days post-immunization, spleen are harvested and the frequency of IFN-γ-
producing CD4þ and IFN-γ-producing CD8þ T cells from immunized mice is measured by intracellular cytokine staining following 5 days in vitro culture after infection for
1 h with DK/96 or SC/18 virus. Statistical signiﬁcance is determined by two-way ANOVA. ** indicates statistical signiﬁcance (po0.01) between Dk/96-Hu and Dk/96-wt
vaccine, *** po0.001.
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adult ferrets were vaccinated with 90 mg or 30 mg of inactivated
DK/96-wt or DK/96-Hu vaccine and the antibody responses were
measured after 21 days. As shown in Fig. 6A, 3 of 6 ferrets that
received 90 mg of DK/96-Hu mutant vaccine reached an HI titer of
40 or greater against both virus antigens (left and right panels). In
contrast, HI responses among DK/96-wt (90 mg) vaccinated ferrets
were signiﬁcantly lower. HI titers among DK/96-wt vaccinated
ferrets (against DK/96-wt virus antigen) were approximately
3-fold lower than that from the DK/96-Hu vaccine group (GMT¼7
versus 25 at the 90 mg dose and GMT¼5 versus 14 for 30 mg dose)
(Fig. 6A; left panel). As observed above, in the HI assay, antibody
titers measured against DK-96-Hu virus antigen were consistently
lower than the HI titers against DK/96-wt antigen; only ferrets
that received 90 mg of DK/96-Hu mutant vaccine induced a
detectable HI response (Fig. 6A; right panel). Neutralizing antibody
responses followed a similar pattern; neutralizing titers from
DK/96-wt vaccinated animals were 2–3-fold lower (against both
DK/96-wt and DK/96-Hu antigens) compared to antibody titers
induced by DK/96-Hu vaccine at both doses (Fig. 6B; left and right
panels).
Next, we evaluated the vaccine protective efﬁcacy following
DK/96-wt virus challenge. Because viral challenge with 106 EID50
Fig. 6. Vaccination of DK/96 vaccines in ferrets. Ferrets (4–6 per group) are vaccinated with 30 or 90 mg of inactivated whole DK/96-wt or DK/96-Hu virus vaccines or PBS
mock control. Serum samples are collected at 21 days post-vaccination to determine anti-DK/96-wt or anti-DK/96-Hu speciﬁc HI (A) or neutralizing antibody titers (B).
Individual symbols represent each experimental ferret, and horizontal lines represent the geometric means (GMT). The limit of detection for both HI and neutralizing tests is
log 3:322 (or 10). If the titer is below detecting limit, it is assigned as log
2:32
2 (or 5). Statistical signiﬁcances are determined by two-way ANOVA and Bonferroni post-test, and
double asterisks indicate the signiﬁcant difference in antibody titers with po0.01 and a single asterisk indicates the signiﬁcant difference in antibody titers with po0.05.
At 21 days post-vaccination, ferrets are challenged with 106 EID50 of DK/96-wt virus and nasal wash samples are collected at days 2, 4, 6 and 8 post-challenge. Mean viral
titers of each group are shown as log10 EID50/mlþSD (C). Statistical signiﬁcances are determined by two-way ANOVA and Bonferroni post-test. An asterisk indicates a
statistically signiﬁcant (po0.05) reduction in virus titers compared to PBS mock group.
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of DK/96-wt virus caused only mild, transient weight loss (3%
mean maximum weight loss in PBS control group), viral titers in
ferret nasal washes were the primary measurement of vaccine
protection. On days 2 and 4 p.c., DK/96-wt and DK/96-Hu vaccine
groups showed comparable viral titers in nasal washes, which
were not signiﬁcantly different from PBS mock controls (Fig. 6C).
At day 6 p.c., all nasal washes from vaccinated groups were
negative for infectious virus, whereas the PBS control group still
shed high titers of virus. Taken together, these data suggest that
avian H1N1 (DK/96) inactivated vaccine with human receptor
binding speciﬁcity is able to induce slightly higher HI and
neutralizing antibodies; however this does not correlate with
increased protection in ferrets.
Discussion
Vaccines derived from avian inﬂuenza viruses have proved
poorly immunogenic in mammals compared to seasonal inﬂuenza
vaccines, which possess an “human-like” α2,6-SA binding prefer-
ence (Atmar et al., 2006; Bresson et al., 2006; Couch et al., 2012;
Keitel et al., 2008; Patel et al., 2012). Therefore, there is a need to
develop improved avian inﬂuenza vaccines for optimal protection
against human infection. In the past ten years, there have been
many different approaches to increase the efﬁcacy of avian
inﬂuenza vaccines, including increasing HA content (Beigel et al.,
2009; Treanor et al., 2006), incorporation of adjuvants (Bernstein
et al., 2008) and modiﬁcation of HA glycan composition (Wang
et al., 2009). In our current study, we mutated the HA of two H1N1
viruses to determine whether α2,3-SA receptor binding speciﬁcity
of avian inﬂuenza viruses contributes to the relatively poor
immunogenicity of these vaccines. Our approach was to use
viruses that were different only in the HA receptor binding site.
We demonstrated in both mouse and ferret models that changing
the receptor binding speciﬁcity from avian- to human-like of an
avian H1N1 virus vaccine can increase antibody titers 2–4 fold and
increase the expression of cytokine secreting CD4 T cells. Interest-
ingly, in our reciprocal approach in which we altered the 1918
virus vaccine receptor binding speciﬁcity from human- to avian-
like, we found that the difference in antibody titers induced by the
two vaccines was less evident. Perhaps the intrinsic trait asso-
ciated with each speciﬁc inﬂuenza virus might inﬂuence how the
key residues in the receptor binding site contribute to viral
immunogenicity. Although the enhanced immunogenicity result-
ing from changing receptor binding speciﬁcity was rather modest
compared to the effects observed by adding adjuvants (Bernstein
et al., 2008; Dong et al., 2012), it nevertheless might provide
an additional approach to improve seroconversion rates among
vaccinated subjects.
Inﬂuenza virus receptor binding speciﬁcity has been shown to
be one of the main determinants in viral tropism and transmissi-
bility (Pappas et al., 2010; Tumpey et al., 2007). It is generally
believed that the respiratory tract tropism of human inﬂuenza
viruses correlates with the abundance of α2,6-SA in upper respira-
tory tract of humans whereas avian inﬂuenza viruses prefer α2,3
linkages mostly located in the lower respiratory tract (Ito et al.,
1998; Shinya et al., 2006). However, the concept that avian
inﬂuenza viruses have a preference of viral infection for the lower
respiratory tract of mammals is likely an oversimpliﬁcation, and
there may be a sufﬁcient number of α2,3-linked SA receptors in
the upper mammalian airway to support signiﬁcant viral replica-
tion (Nicholls et al., 2007; Zeng et al., 2013). For example, avian
H5N1 viruses with α2,3 receptor preference are capable of infect-
ing human upper respiratory tract tissues and have been shown
to replicate as efﬁciently as human inﬂuenza viruses in ferret
tracheal epithelial (FTE) cells that predominantly express α2,6-SA
(Zeng et al., 2013). Interestingly, in the aforementioned study,
H5N1 virus replicated as efﬁciently as human inﬂuenza (H3N2 and
H1N1) viruses in FTE cells despite its low initial infection rate and
less abundant avian-like (α2,3-linked) receptors for H5N1 virus to
initiate an infection. Moreover, although α2,3-SA had been shown
to be dominant in mouse respiratory tracts (Ibricevic et al., 2006),
we were able to demonstrate that changing receptor binding
speciﬁcity for either DK/96 or SC/18H1N1 virus had no signiﬁcant
effect on viral titers in mouse lung tissues. Our ﬁnding is
consistent with the recent study in which the authors reported
that modulating receptor binding speciﬁcity for the 2009 pan-
demic virus from α2,6-SA binding to α2,3-SA binding did not
enhance viral replication in mice (Lakdawala et al., 2013). Similar
results have also been shown in ferrets, which share great
similarities with humans in SA distribution in respiratory tracts
(Jayaraman et al., 2012). Both studies with the SC/1918 virus and
2009 pandemic virus revealed that the viruses with either α2,3-SA
or α2,6-SA binding preference showed no difference in viral
replication in upper and lower respiratory tracts of ferrets
(Lakdawala et al., 2013; Tumpey et al., 2007). However, there are
other seemingly contradictory reports as well. Xu et al. showed
that the recombinant mutant Solomon Island/3/06 (SI/06) virus
(190A/226Q) with exclusive α2,6-SA binding speciﬁcity replicated
in both upper and lower respiratory tracts, whereas the mutant
virus (190D/226 R) with α2,3-SA binding preference only repli-
cated in ferret nasal turbinate (Xu et al., 2010). Another study with
H2 and H6 viruses also showed that the α2,6-SA binding viruses
with either 226L/228G or 226Q/228S replicated signiﬁcantly better
in the upper respiratory tract of ferrets compared to the α2,3-SA
binding virus with 226Q/228G amino acids (Chen et al., 2012).
Taken together, it appears that the mutations that affect the
receptor binding site for vaccine development do not affect viral
ﬁtness or result in an attenuated virus.
The data also demonstrated that changing receptor binding
speciﬁcity of the DK/96 vaccine from avian- to human-like by
substitution at residues 190 and 225 had no effect on viral
antigenicity based on the cross-reactive HI responses. During the
interpretation of HI results we consistently observed that the HI
titers against DK-96-Hu virus antigen were approximately 2–4 fold
lower than HI titers against DK/96-wt antigen regardless of the
viruses used for immunization. This initially suggested to us that
there were differences in antigenicity between the parental
and mutant viruses. However, the neutralization antibody titers
against DK/96-Hu virus were not lower but actually slightly higher
(less than 2-fold) than the titers against DK/96-wt virus. Thus, a
minor confounding issue with the HI assay in these studies is that
turkey RBCs used to detect the HI titers against DK/96-Hu antigen
are less sensitive than the horse RBCs used to detect DK/96-wt
antigen. We speculated that the differences in cross-reactive
antibody HI titers were mostly due to the changes in the
sensitivity of the assays rather than the changes in viral anti-
genicity. Previous studies of live virus infection of ferrets demon-
strated that changing receptor binding speciﬁcity through the
speciﬁc residues (190/226 for H1 virus or 226/228 for H2 and H6
viruses) caused a change in viral antigenicity and an approxi-
mately 10-fold difference in antibody titers against homologous
viruses in ferrets (Chen et al., 2012; Xu et al., 2010). Therefore,
depending on virus subtypes, vaccine formats, and the speciﬁc
residues targeted, the effect of changing receptor binding pre-
ference on viral antigenicity and immunogenicity may vary.
In our study, we observed that H1 subtype vaccines with
human receptor binding preference induced slightly higher levels
of humoral and cell-mediated responses. There are still many
unknowns concerning the interaction of inﬂuenza HA and their
receptors. In particular, the interaction of HA with sialic acid
receptors of antigen presenting cells (e.g. dendritic cells [DCs],
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and macrophages) leading to activation of the immune response is
not well understood. Although SA has long been identiﬁed as the
primary receptor for inﬂuenza virus entry into host epithelium,
where inﬂuenza viruses primarily replicate (Skehel and Wiley,
2000), there is growing evidence suggesting that several speciﬁc
cell receptors are involved in virus entry into certain cell types,
especially immune cells. DC-speciﬁc intercellular adhesion
molecule-3-grabbing non-integrin (DC-SIGN) (Londrigan et al.,
2011; Wang et al., 2008) along with other calcium-dependent
(C-type) lectin receptors, including macrophage mannose receptor
(MMR) (Reading et al., 2000), SIGNR (L-SIGN) (Londrigan et al.,
2011) and macrophage galactose-speciﬁc -type lectin (MGL)
(Upham et al., 2010) has been shown to be able to mediate viral
entry in either SA-dependent or SA-independent manner depend-
ing on the cell types and the viruses used in the studies. The
C-type lectin receptor-mediated interaction between immune cells
and inﬂuenza glycoproteins has been shown to be important not
only in cell tropism and pathogenesis, but also in inducing host
immune responses. This has been demonstrated both in vitro with
SIGN-R1-speciﬁc antibody and in vivo using multiphoton intra-
vital imaging of DCs which showed that the uptake of inactivated
PR8 virus via SIGN-R promoted humoral immunity (Gonzalez
et al., 2010). In addition to C-type lectins, other unidentiﬁed
receptors may also be involved in virus binding to immune cells
as suggested from the recent work of Ramos et al. in which
authors used two isogenic recombinant A/Vietnam/2004 (H5N1)
viruses to study the effects of receptor binding speciﬁcity on the
innate immune response. They found that the virus (226Q/228G)
with avian-type receptor binding speciﬁcity induced higher levels
of proinﬂammatory cytokines in comparison to the virus (226L/
228S) with human receptor binding speciﬁcity (Ramos et al.,
2011). The authors propose that the receptors on APCs that
recognize α2,3-SA may be different from those that recognize
α2,6-SA-binding viruses leading to distinct immune responses.
Although our results failed to demonstrate that receptor bind-
ing speciﬁcity contributes substantially to the immunogenicity of
avian inﬂuenza vaccines, the research suggests that additional
studies are needed to determine whether modifying the HA of
current WHO avian inﬂuenza candidate vaccine viruses (http://
www.who.int/en/) could improve the immunogenicity. It would be
of interest to investigate whether the substitutions identiﬁed in
transmissible H5N1 virus studies (Chen et al., 2012; Herfst et al.,
2012; Imai et al., 2012) can lead to an improvement in vaccine
immunogenicity. Furthermore, it would be interesting to evaluate
whether α2,6 SA receptor binding mutant vaccines can be further
improved by either additional modiﬁcation of the glycan composi-
tion of the HA and/or addition of adjuvants.
Materials and methods
Inactivated virus vaccines
A set of eight reverse genetics plasmids cloned into the
expression vector pDZ was used for rescuing the avian A/Duck/
New York/15024–21/96 (Dk/96) H1N1 virus as described pre-
viously (Van Hoeven et al., 2009). The rescue plasmids encoding
individual segments of A/Puerto Rico/8/1934 (PR8) virus were
kindly provided by Adolfo García-Sastre (Mount Sinai School of
Medicine, New York). The HA and NA genes of A/South Carolina/
1/1918 (SC/18) H1N1 virus were ampliﬁed and cloned into a
reverse genetics vector pPOL as previously reported (Tumpey
et al., 2007). The Agilent QuikChange site-directed mutagenesis
kit (Santa Clara, CA) was used to introduce mutations into pDZ-
Dk/96-HA or pPOL-SC/18-HA at residues 190 and 225. The recom-
binant wild-type (wt) Dk/96 and mutant DK/96 virus with HA
amino acid substitutions at 190D and 225D bound preferentially
to the human-like (α2,6 SA) receptor (hereafter referred to as
Dk/96-Hu) were previously described (Van Hoeven et al., 2009). A
recombinant virus containing the wt HA and NA genes from SC/18
virus (PR8:1918-HA/NA; 6:2) (SC/18-wt) along with a α2,3 SA
receptor binding mutant virus with HA mutations at positions
190E and 225G (PR8:1918-HA-Av/NA; 6:2) (SC/18-Av) was rescued
on the PR8 virus backbone (Tumpey et al., 2007). The recombinant
viruses were propagated in the allantoic cavities of 10-day-old
embryonating chicken eggs at 35 1C for 48 h. The allantoic ﬂuids
were pooled, clariﬁed by centrifugation and the HA and NA genes
of each recombinant virus were conﬁrmed by sequencing to
ensure no undesired mutations.
Viruses used as vaccines were concentrated from allantoic ﬂuid
and puriﬁed by equilibrium density centrifugation through a
30–60% linear sucrose gradient as previously described (Shaw
et al., 2008). The concentrations of puriﬁed virus vaccines were
determined by a Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, CA) and then diluted to 1 mg/ml before inactivation with
0.025% formalin at 4 1C for at least 48 h. Virus inactivation was
conﬁrmed by two passages in embryonated eggs. Proteins of the
puriﬁed viruses were separated by 4–15% Mini-PROTEAN Tris/
Glycine precast gel (Bio-Rad) and stained with Coomassie blue.
The images were captured by Kodak Image Station 4000R Pro
and analyzed by Kodak Molecular Imaging Software. The ratio of
the HA proteins (HA0) to the total proteins (HA0, NP, M) was
determined according to the method described previously (Harvey
et al., 2008).
Hemagglutination assay
Hemagglutination assays using resialyated turkey red blood
cells were performed as previously described (Glaser et al., 2005).
Brieﬂy, turkey red blood cells were enzymatically desialyated
using Vibrio cholerae Sialidase (Roche-Applied Science, Indianapo-
lis, IN) followed by resialylation using either α2-6-(N)-sialyltrans-
ferase or α2-3-(N)-sialyltransferase (Sigma-Aldrich, St. Louis, MO).
Hemagglutination assays were performed by using 8 hemaggluti-
nation units (HAU) of virus.
Immunization and challenge of mice and ferrets
All animal experiments were performed under the guidance
of the Centers for Disease Control and Prevention's Institutional
Animal Care and Use Committee and were conducted in an
Association for Assessment and Accreditation of Laboratory Ani-
mal Care International-accredited animal facility. Groups of 10
female BALB/c mice (Charles River Laboratories, Wilmington, MA),
6–8 weeks old, were vaccinated intramuscularly (i.m.) with 100 ml
of PBS-diluted inactivated whole virus vaccine following anesthe-
sia with 0.2 ml of 2,2,2-tribromoethanal in tert-amly alcohol
(Avertin; Aldrich Chemical Co., Milwaukee, WI). The dose of each
vaccine was determined by measurement of total protein content
(described above) and adjusted based on the percentage of HA to
total protein amount to ensure that wt and receptor mutant
vaccines contained the same amount of the HA protein. The ratio
of HA to total protein for two independently prepared vaccines
(wt and receptor mutant viruses) varied over a narrow range of
30–40%. Vaccines were administered as one- or two-dose regimen
given 4 weeks apart between primary and boost vaccination.
Blood was collected using the cheek-pouch method and serum
was isolated from individual mice at the indicated days post-
vaccination. Vaccinated mice were challenged intranasally (i.n.)
with 106 EID50 of Dk/96-wt or 106 PFU of SC/18-wt virus (50 ml)
diluted in PBS. Homogenates from whole lungs, collected on day 4
post-challenge (p.c.), were prepared in 1 ml of PBS and viral titers
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were determined by a standard plaque assay in Madin-Darby
canine kidney (MDCK) cells or in embryonating eggs to determine
50% egg-infectious dose (EID50) titers using a statistical method
(Reed, 1938).
For ferret vaccinations, groups of 4–6 adult male Fitch ferrets,
5–8 months of age (Triple F farms, Sayre, PA), serologically
negative by hemagglutination-inhibition (HI) assay for currently
circulating inﬂuenza viruses, were used in this study. Ferrets were
given 30 or 90 mg of inactivated whole-virus vaccine i.m. diluted in
1 ml of sterile PBS. Serum samples were collected at three weeks
post-vaccination for serologic assays. The vaccinated ferrets were
challenged i.n. with 1 ml of 106 EID50 of DK/96-wt virus diluted in
PBS following anesthesia with a ketamine–xylazine–atropine
cocktail given i.m. Nasal wash samples were collected on indicated
days and titrated in embryonated eggs.
Serologic assays
Mouse and ferret sera were treated with receptor destroying
enzyme (RDE) from Vibrio cholerae (Denka Seiken, Tokyo) over-
night followed by heat treatment (56 1C, 30 min) and prediluted
1:10 before use in the HI assay or neutralization assay. HI assay
was performed by standard methods using 0.5% turkey red blood
cells for inﬂuenza viruses with human receptor binding speciﬁcity
(SC/18-wt and DK/96-Hu) or with 1% of horse red blood cells for
the H1N1 viruses with avian receptor binding speciﬁcity (SC/18-Av
and DK/96-wt). HI titer was determined by reciprocal of the
highest dilution of serum that completely inhibited haemaggluti-
nation. Neutralizing antibody titers were determined according to
previously established methods (Mozdzanowska et al., 1997) and
the titers were shown as the reciprocal of the highest dilution of
serum that neutralized 100 plaque forming units (PFU) of virus in
MDCK cell cultures.
Virus speciﬁc antibody-secreting cell (ASC) enzyme-linked
immunosorbent spot (ELISPOT) assay
The frequency of virus-speciﬁc ASC cell ELISPOT assays was
performed according to established methods (Jeisy-Scott et al.,
2012). Brieﬂy, PVDF multiscreen 96-well plates (Millipore, Bill-
erica, MA) were coated with 5 mg/ml anti-mouse IgG antibody
(Southern Biotech, Birmingham, AB) for measuring total IgG
secreting B cells. In separate plates, inactivated WT or receptor
mutants of DK/96 or SC/18 virus were adjusted to 100 HAU and
incubated overnight at 4 1C. The plates were washed thrice with
PBS and then blocked for 1 h at 37 1C with 200 ml/well of RPMI-
1640 supplemented with 10% FBS, penicillin/streptomycin, L-glu-
tamine, and 0.01 M HEPES buffer (cRPMI). Groups of ﬁve vacci-
nated mice were euthanized at 14 days post-primary vaccination
and single cell suspensions of splenocytes were prepared after
red blood cell lysis. Suspensions were adjusted to 10106–
15106 cells/ml and added onto homologous virus-coated plates
and incubated overnight in a 37 1C, 5% CO2 incubator. The plates
were washed 4 times with 0.5% Tween 20 in PBS (PBST) and
incubated with biotinylated anti-mouse IgG antibodies (Southern
Biotech) for 1 h at room temperature. Plates were washed 4 times
with PBST, and incubated with alkaline phosphatase-conjugated
streptavidin (Vector, Burlingame, CA) in PBST for 1 h at room
temperature. Plates were washed 4 times and spot development
was achieved by adding 100 ml of Vector Blue alkaline phosphatase
substrate kit III (Vector, Burlingame, CA) to each well. Spot forming
units were counted using ImmunoSpots (Cellular Technology Ltd.,
Cleveland, OH) and expressed as % Ag-speciﬁc IgGþB cells out of
total IgG -secreting B cells.
Cytokine secreting CD4, CD8 T cells
Suspensions of 1106 splenocytes were seeded in 100 ml RPMI
medium in 96-well round bottom plates and infected by wt or
receptor mutants of DK/96 or SC/18 virus at a multiplicity of
infection (MOI) of 0.1, as described (Jeisy-Scott et al., 2012). After
1 h incubation with the virus, 50 ml RPMI containing 40% FBS and
400 U/ml Penicillin and 400 μg/ml streptomycin solution was
added. Four days post-infection, the cells were collected and re-
stimulated with plate-bound anti-CD3 (10 μg/ml; clone 145-2C11;
eBioscience, San Diego, CA), and anti-CD28 (2 μg/ml, clone 37.51;
eBioscience) for 6 h in the presence of BD GolgiStop™ and
GolgiPlug™ protein transport inhibitors (BD Bioscience, San Jose,
CA) to enhance intracellular cytokine staining. Cells were
surface stained with PE-Cy™7-conjugated anti-CD4 (clone GK1.5;
eBioscience) and Alexa Fluor 700-conjugated anti-CD8 (53-6.7; BD
Bioscience) for 20 min at 4 1C. Cells were then made permeable
with Cytoﬁx/Cytoperm (BD Bioscience) followed by intracellular
staining with PerCP-Cy5.5-conjugated anti-IFN-γ (BioLegend, San
Diego, CA) for 45 min at 4 1C. Cells were washed twice with perm/
wash and re-suspended in PBS/10% FBS. Samples were analyzed
using an LSR II ﬂow cytometer (BD Biosciences, Sam Jose, CA), and
the cytometry data were analyzed using FlowJo software (TreeStar,
Ashland, OR).
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